It refers to a method of using 8-32 mg of sustained release steroid or drug acceptable release salt and 90-360 mg of sustained release polypropylene or drug acceptable salt, the purpose of which is to reduce the risk of cardiovascular disease or adverse events, This includes patients with serious cardiovascular adverse events, preferably those who are likely to develop adverse cardiovascular disease or mace, who may be overweight or obese.Se refiere a un metodo para utilizar 8 a 32 mg de naltrexona de liberacion sostenida o una sal farmaceuticamente aceptable de la misma y 90 a 360 mg de bupropion de liberacion sostenida o una sal farmaceuticamente aceptables, con el proposito de reducir el riesgo de padecer desenlaces o eventos adversos cardiovasculares, lo cual incluye los eventos adversos cardiovasculares graves (MACE) en los sujetos, preferiblemente, en aquellos cuyo riesgo de sufrir desenlaces cardiovasculares adversos o MACE es mayor, que puedan tener sobrepeso o ser obesos
